Proteolysis-targeting chimeras and their implications in breast cancer

Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Angeles C. Tecalco-Cruz, Jesús Zepeda-Cervantes, Josué O. Ramírez-Jarquín, Alberto Rojas-Ochoa
Formato:	article
Lenguaje:	EN
Publicado:	Open Exploration Publishing Inc. 2021
Materias:	estrogen receptor alpha breast cancer degradation via the ubiquitin-proteasome system proteolysis-targeting chimeras Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/cde825929f7b48548b8659148429155f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cde825929f7b48548b8659148429155f
record_format	dspace
spelling	oai:doaj.org-article:cde825929f7b48548b8659148429155f2021-11-17T01:48:03ZProteolysis-targeting chimeras and their implications in breast cancer10.37349/etat.2021.000602692-3114https://doaj.org/article/cde825929f7b48548b8659148429155f2021-11-01T00:00:00Zhttps://www.explorationpub.com/Journals/etat/Article/100260https://doaj.org/toc/2692-3114Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER and HER2 targeted therapies have been employed in BC treatment. However, resistance to these therapies has been reported, indicating a need for developing novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) are new, promising therapeutic tools designed with a bimodular structure: one module allows specific binding to target proteins, and the other module allows efficient degradation of these target proteins. In this paper, PROTACs and their potential in controlling the progression of ERα and HER2+ BC are discussed.Angeles C. Tecalco-CruzJesús Zepeda-CervantesJosué O. Ramírez-JarquínAlberto Rojas-OchoaOpen Exploration Publishing Inc.articleestrogen receptor alphabreast cancerdegradation via the ubiquitin-proteasome systemproteolysis-targeting chimerasInternal medicineRC31-1245ENExploration of Targeted Anti-tumor Therapy, Vol 2, Iss 6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	estrogen receptor alpha breast cancer degradation via the ubiquitin-proteasome system proteolysis-targeting chimeras Internal medicine RC31-1245
spellingShingle	estrogen receptor alpha breast cancer degradation via the ubiquitin-proteasome system proteolysis-targeting chimeras Internal medicine RC31-1245 Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa Proteolysis-targeting chimeras and their implications in breast cancer
description	Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER and HER2 targeted therapies have been employed in BC treatment. However, resistance to these therapies has been reported, indicating a need for developing novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) are new, promising therapeutic tools designed with a bimodular structure: one module allows specific binding to target proteins, and the other module allows efficient degradation of these target proteins. In this paper, PROTACs and their potential in controlling the progression of ERα and HER2+ BC are discussed.
format	article
author	Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa
author_facet	Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa
author_sort	Angeles C. Tecalco-Cruz
title	Proteolysis-targeting chimeras and their implications in breast cancer
title_short	Proteolysis-targeting chimeras and their implications in breast cancer
title_full	Proteolysis-targeting chimeras and their implications in breast cancer
title_fullStr	Proteolysis-targeting chimeras and their implications in breast cancer
title_full_unstemmed	Proteolysis-targeting chimeras and their implications in breast cancer
title_sort	proteolysis-targeting chimeras and their implications in breast cancer
publisher	Open Exploration Publishing Inc.
publishDate	2021
url	https://doaj.org/article/cde825929f7b48548b8659148429155f
work_keys_str_mv	AT angelesctecalcocruz proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT jesuszepedacervantes proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT josueoramirezjarquin proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT albertorojasochoa proteolysistargetingchimerasandtheirimplicationsinbreastcancer
_version_	1718426075004928000

Proteolysis-targeting chimeras and their implications in breast cancer

Ejemplares similares